Imaging Small Cell Cancer with Monoclonal Antibody SWA11
Author Information
Author(s): A. Smith, R. Waibel, G. Westera, A. Martin, A.T. Zimmerman, R.A. Stahel
Primary Institution: University Hospital, Zurich, Switzerland
Hypothesis
Can the monoclonal antibody SWA11 effectively localize to small cell carcinoma xenografts in vivo?
Conclusion
The monoclonal antibody SWA11 shows strong selective accumulation in small cell carcinoma xenografts, indicating its potential for imaging and therapy.
Supporting Evidence
- SWA11 showed a tumor to blood ratio of 7.5:1 at day 4 post-injection.
- The antibody localized to tumors with 10.5% of the total injected material per gram of tumor at day 2.
- External gamma scintigraphy confirmed the selective accumulation of SWA11 in tumors.
Takeaway
Researchers created a special antibody that can find and stick to small cell lung cancer cells, helping doctors see where the cancer is in the body.
Methodology
The study involved generating a monoclonal antibody, testing its binding to cancer cells in vitro, and evaluating its localization in mice with xenografts.
Limitations
The study primarily focused on a single type of cancer and may not be generalizable to other cancer types.
Participant Demographics
Female NMRI nu/nu mice were used for the xenograft model.
Want to read the original?
Access the complete publication on the publisher's website